Affimed (AFMD) Stock Price

Affimed Price

NASDAQ·CLOSED
0.16
​
Market closed

Revenue has compounded at 19.4% per year over the past 11 years to 8.28 M EUR. Affimed's net margin stands at -1,280.2%, down from -151.3% several years earlier.

Affimed stock price

Access this data via the Eulerpool API

Affimed business model & stock analysis

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. The company is headquartered in Heidelberg, Baden-Wuerttemberg and currently employs 128 full-time employees. The company went IPO on 2014-09-12. The firm's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The firm is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Frequently asked questions about Affimed

10 analysts currently rate the Affimed stock: 9 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Affimed to generate revenue of 14.71 M EUR and earnings per share of -2.21 EUR.

The Affimed share (AFMD) is listed on 7 stock exchanges, including: NASDAQ (AFMD), London (0HL9.L), SIX (Zürich) (A28.SW), Frankfurt (A28.F), München (A28.MU), Düsseldorf (A28.DU).

The expected revenue of Affimed is 14.71 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Affimed is -33.07 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Affimed is currently -0.07. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Affimed stock.

The price-to-sales ratio (P/S) of Affimed is currently 0.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Affimed stock.

The Eulerpool Quality Score for Affimed is 2/10.

The ISIN of Affimed is NL0015001ZQ0. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Affimed is A12BHU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Affimed is AFMD. The ticker symbol is used to trade Affimed shares on the stock exchange.

Fair ValueTerminal
0.13 EUR
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
64,648.44 EUR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website affimed.com
Country
Currency
EUR
Initial public offering
Sep 12, 2014
ISIN
NL0015001ZQ0
Cusip
N01045108
Sedol
BQQF5R2
Market capitalization
2.37 M EURMicro Cap
52-Week Range
PEG
0.00
P/E ratio
P/Ee 2024
-0.04
P/Ee 2025
-0.08
P/Ee 2026
-0.07
P/Ee 2027
-0.06
P/Ee 2028
-0.07
P/S
P/Se
3.21
EV/EBIT
0.52
P/B Ratio
0.04
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-137.30 %
Last updated Oct 11, 2026, 7:49 PM

Affimed Ticker

DÜSSELDORF · A28.DUFRANKFURT · A28.FLONDON · 0HL9.LLONDON STOCK EXCHANGE · 0HL9.LMUNICH · A28.MUNASDAQ · AFMDSIX · A28.SW

All fundamentals and in-depth analysis of Affimed

Our stock analysis for Affimed stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Affimed. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.